Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection

Global pharmaceutical leader, Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial.

The U.S. FDA has tentatively approved Lupin's Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial as bioequivalent to Merck's Bridion® Injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.

Shares of Lupin Limited was last trading in BSE at Rs. 2312.70 as compared to the previous close of Rs. 2334.95. The total number of shares traded during the day was 25593 in over 2800 trades.

The stock hit an intraday high of Rs. 2333.85 and intraday low of 2295.70. The net turnover during the day was Rs. 59160765.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals TentativeApproval USFDA SugammadexInjection